Compare Johnson & Johnson (JNJ) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Johnson & Johnson trades at $260.67 (market cap $618.09B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $48.46 (market cap $73.20B). The key difference: Johnson & Johnson is far larger — about 8.4× Vanguard Sht-Term Inflation-Protected Sec Idx ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days on average.
| JNJ | VTIP | |
|---|---|---|
Market Cap | $618.09B | $73.20B |
Volume | 6,050,983 | 2,511,360 |
Sector | Health | — |
52-Week High | $278.43 | $50.46 |
52-Week Low | $186.00 | $48.38 |
Typical Hold Time | 129 Days | 91 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
VTIP trades at $48.46, showing minimal daily movement with a slight decline of 0.01%. Technical indicators present a mixed picture with bearish moving averages but bullish oscillators, including oversold RSI readings. The ETF focuses on short-term inflation-protected securities, offering protection against rising inflation while minimizing interest rate sensitivity. Recent institutional activity shows increased positions from firms like NewEdge Advisors and 55 North Private Wealth.
The outlook for VTIP remains tied to inflation dynamics and Federal Reserve policy. With inflation persisting above the 2% target, short-duration TIPS provide strategic hedging value. However, the fund faces risks from potential Fed policy shifts and real yield fluctuations. Current technical weakness suggests near-term pressure, but oversold conditions may present entry opportunities for inflation-conscious investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
